HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough

This article was originally published in The Rose Sheet

Executive Summary

Firm announces preliminary plans to relocate 350 consumer health care and animal care employees to new Summit, N.J. campus. The move is expected to be complete by year-end, Schering-Plough states. The site will be used for both office space and R&D operations and eventually will house approximately 1,700 employees, according to the company. "We plan to develop Summit into Schering-Plough's second-largest campus in New Jersey," next to the firm's Kenilworth headquarters, CEO Fred Hassan says. Satellite offices that may be affected by the move include a leased facility in Berkeley Heights, where the consumer health care business is located, two leased offices in Cranford and company-owned buildings in Madison, Springfield and Union. The project is not expected to result in any lay-offs, the firm adds...

You may also be interested in...



Formycon Chief Sees COVID-19 Boosting Biosimilars

Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.

PDUFA Renewal Negotiations: What Does Industry Want Now?

With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.

Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

UsernamePublicRestriction

Register

SC142283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel